Ken Griffin Cytom X Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $2,800 - $3,775	-2,500 Reduced 45.45%	3,000 $3,000
Q2 2024 Aug 14, 2024	SELL	$1.21 - $5.13 $4,114 - $17,442	-3,400 Reduced 38.2%	5,500 $6,000
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $14,946 - $29,044	-10,600 Reduced 54.36%	8,900 $19,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $16,050 - $23,250	-15,000 Reduced 43.48%	19,500 $30,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $756 - $1,122	-600 Reduced 1.71%	34,500 $44,000
Q2 2023 Aug 14, 2023	BUY	$1.41 - $1.92 $28,905 - $39,360	20,500 Added 140.41%	35,100 $60,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $4,736 - $9,216	-3,200 Reduced 17.98%	14,600 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $2,975 - $4,775	2,500 Added 16.34%	17,800 $28,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $738 - $1,182	600 Added 4.08%	15,300 $22,000

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.